



**HAL**  
open science

## **Photochemistry on the Space Station-Antibody Resistance to Space Conditions after Exposure Outside the International Space Station**

Gaëlle Coussot, Aurélie Le Postollec, Clément Faye, Mickaël Baqué, Odile Vandenabeele-Trambouze, Sébastien Incerti, Flavie Vigier, Didier Chaput, Hervé Cottin, Bartos Przybyla, et al.

► **To cite this version:**

Gaëlle Coussot, Aurélie Le Postollec, Clément Faye, Mickaël Baqué, Odile Vandenabeele-Trambouze, et al.. Photochemistry on the Space Station-Antibody Resistance to Space Conditions after Exposure Outside the International Space Station. *Astrobiology*, 2019, 19 (8), pp.1053-1062. 10.1089/ast.2018.1907 . hal-02272609

**HAL Id: hal-02272609**

**<https://hal.science/hal-02272609>**

Submitted on 30 May 2024

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

---

## Photochemistry on the Space Station-Antibody Resistance to Space Conditions after Exposure Outside the International Space Station

Coussot Gaelle <sup>1,\*</sup>, Le Postollec Aurelie <sup>2</sup>, Faye Clement <sup>3</sup>, Baque Mickael <sup>4</sup>,  
Vandenabeele-Trambouze Odile <sup>5</sup>, Incerti Sebastien <sup>6</sup>, Vigier Flavie, Chaput Didier <sup>7</sup>, Cottin Herve <sup>8,9</sup>,  
Przybyla Bartos <sup>10</sup>, Berger Thomas <sup>10</sup>, Dobrijevic Michel <sup>2</sup>

<sup>1</sup> Univ Montpellier, ENSCM, CNRS, IBMM, F-34093 Montpellier 5, France.

<sup>2</sup> Univ Bordeaux, CNRS, LAB, Pessac, France.

<sup>3</sup> Colcom, Cap Alpha, Clapiers, France.

<sup>4</sup> German Aerosp Ctr DLR, Inst Planetary Res Management & Infrastruct, Res Grp Astrobiol Labs, Berlin, Germany.

<sup>5</sup> UBO, IUEM UMR 6197, LMEE, Plouzane, France.

<sup>6</sup> Univ Bordeaux, UMR 5797, CENBG, Gradignan, France.

<sup>7</sup> Ctr Natl Etud Spatiales, DCT ME EM, Toulouse, France.

<sup>8</sup> Univ Paris Est Creteil, UMR 7583, LISA, Creteil, France.

<sup>9</sup> Univ Paris Diderot, Inst Pierre Simon Lapl, Creteil, France.

<sup>10</sup> German Aerosp Ctr, Inst Aerosp Med, Cologne, Germany.

\* Corresponding author : Gaelle Coussot, email address : [gaelle.coussot@umontpellier.fr](mailto:gaelle.coussot@umontpellier.fr)

---

### Abstract :

Antibody-based analytical instruments are under development to detect signatures of life on planetary bodies. Antibodies are molecular recognition reagents able to detect their target at sub-nanomolar concentrations, with high affinity and specificity. Studying antibody binding performances under space conditions is mandatory to convince space agencies of the adequacy of this promising tool for planetary exploration.

To complement previous ground-based experiments on antibody resistance to simulated irradiation, we evaluate in this paper the effects of antibody exposure to real space conditions during the EXPOSE-R2 mission outside the International Space Station. The absorbed dose of ionizing radiation recorded during the 588 days of this mission (220 mGy) corresponded to the absorbed dose expected during a mission to Mars. Moreover, samples faced, at the same time as irradiation, thermal cycles, launch constraints, and long-term storage. A model biochip was used in this study with antibodies in freeze-dried form and under two formats: free or covalently grafted to a solid surface.

We found that antibody-binding performances were not significantly affected by cosmic radiation, and more than 40% of the exposed antibody, independent of its format, was still functional during all this

---

experiment. We conclude that antibody-based instruments are well suited for in situ analysis on planetary bodies.

**Keywords** : Astrobiology, Cosmic rays, Biochip, Antibody, Planetary exploration

## 51 **Introduction**

52 In the context of planetary exploration, the use of miniaturized instruments based on target-  
53 binding reagent with high specificity and binding affinity is clearly relevant. Indeed, such  
54 instruments can, in principle, detect unambiguously thousands of different targets from small  
55 molecules like amino acids to complex molecules and microorganisms in a single assay. The  
56 basic principle can be summarized as follow: the target-binding reagents, like antibodies (Ab),  
57 are fixed on a solid surface to specifically capture their target. In direct methods, target  
58 interaction with the binding site of Ab and the use of appropriate reagents generate a visible  
59 signal capable of being measured, for instance, by a charge coupled device (CCD) camera. In  
60 the field of astrobiology, several Ab-based biochips have been proposed as miniaturized high  
61 throughput detection systems, to detect biomarkers, especially organic ones, in the search for  
62 extraterrestrial life (Parro *et al.*, 2005; Le Postollec *et al.*, 2007; Parro *et al.*, 2008; Martins *et*  
63 *al.*, 2011; Parro *et al.*, 2011a, Parro *et al.*, 2011b; Sims *et al.*, 2012; McKay *et al.*, 2013; Smith  
64 *et al.*, 2014).

65 However, space is a hazardous environment in particular due to strong irradiation from primary  
66 and secondary particles produced by Galactic Cosmic Rays (GCR) and Solar Energetic Particles  
67 (SEP), temperature variations and long duration storage (during the cruise phase especially).  
68 As a consequence, one main concern relies on the resistance of biochips to these cumulative  
69 space conditions. In recent years, studies have been performed to evaluate the resistance of Ab  
70 to specific space conditions, especially regarding the effect of some ionizing particles on Ab  
71 binding performances (Le Postollec *et al.*, 2009a; Le Postollec *et al.*, 2009b; Baqué *et al.*, 2011;  
72 de Diego-Castilla *et al.*, 2011; Baqué *et al.*, 2017; Coussot *et al.*, 2017). However, these ground-  
73 based simulations were limited due to the use of one single type and energy particle at a time  
74 and the experimental characteristics of the beam (high fluxes in a short exposure time,

75 unidirectional irradiation). In the space environment, biochips would be exposed to continuous  
76 and sporadic fluxes of various particles in a large range of energies and all directions,  
77 concomitantly with other parameters inherent to a space mission including thermal variations,  
78 vibrations and storage conditions.

79 To complement ground-based studies, Derveni *et al.* conducted in 2007 a 12 days mission on  
80 the BIOPAN-6 low Earth orbit platform to demonstrate the effects of cumulative irradiations  
81 on two antibodies' ability to bind to their respective antigens (Derveni *et al.*, 2012; Derveni *et*  
82 *al.*, 2013). The absorbed dose recorded at the samples position by the dosimeters was 2.4  
83 milligrays (mGy) during the experiment. Both freeze-dried Ab, in free format and absorbed into  
84 laser-cut glass fiber pads, were reported as unaffected with regard to their target-binding  
85 abilities after their low Earth orbit platform exposure. Analyses were done with conventional  
86 indirect enzyme-linked immunosorbent assays (ELISA). However, major loss of Ab activities  
87 (>70%) was pointed out and explained by the Ab preparation procedure, in particular the freeze-  
88 drying step and storage time period. These issues complicated the interpretation of the results.  
89 This study highlighted that using Ab as target-binding reagent necessitates controlling its ability  
90 to bind to its target (refers also as its functionality) after each step of the antibody-based device  
91 development. Consequently, for biochips, a control is required after the Ab immobilization onto  
92 the solid surface (to determine the initial rate of functional Ab), but also after washing, freeze-  
93 drying, storage, and rehydration steps. These controls permit to precisely quantify the number  
94 of Ab that remains functional after the preparation procedure and before undergoing some  
95 putative deleterious experiments.

96 In the frame of the BiOMAS project (Biochip for Organic Matter Analysis in Space), we  
97 developed a model biochip, in which a specific Ab (anti-horseradish peroxidase Ab, quoted  
98 anti-HRP Ab hereafter) was used in free format or covalently immobilized onto a solid surface.

99 A direct detection method called “Antibody Anti-HorseRadish Peroxidase (A2HRP)” was  
100 developed and fulfilled the validation criteria requested by the Food and Drug Administration  
101 (FDA) and the European Medicines Agency (EMA) for the validation of bioanalytical methods  
102 (Coussot *et al.*, 2018a, Coussot *et al.*, 2018b). This gold standard method permits to evaluate  
103 accurately and precisely the number of free or immobilized functional Ab (interday variation  
104 <12.1%). The Lower Limit of Quantification (LLOQ) corresponds to  $1.40 \pm 0.18\%$  of the initial  
105 rate of active Ab. The A2HRP method was successfully used in optimizing freeze-drying  
106 conditions to better preserve the Ab functionality, notwithstanding its format (Coussot *et al.*,  
107 2018c), and in evaluating the Ab resistance under various stressful environments (Coussot *et*  
108 *al.*, 2017, Coussot *et al.*, 2018c).

109 In this work, we first summarize our experiment (see also Vigier *et al.* 2013), which was part  
110 of the Photochemistry on the Space Station (PSS) project (Cottin *et al.*, 2015) and the analytical  
111 developments we conducted prior to the final analyses performed on the samples few weeks  
112 after their return to Earth (Coussot *et al.* 2018a, 2018b and 2018c). Both formats, free anti-HRP  
113 Ab and anti-HRP Ab immobilized onto a surface, have been conditioned into a homemade  
114 sample holder unit and installed outside the International Space Station (ISS) on the EXPOSE-  
115 R2 platform. We then present the results on the resistance of our model biochip against a long-  
116 time exposure (more than 18 months) to real space conditions. The relevance of antibody-based  
117 biochips for space exploration is finally discussed.

118

119

## 120 I. Materials and methods

### 121 II.1 Chemical, reagents and materials

122 Mouse monoclonal anti-horseradish peroxidase antibodies (anti-HRP Ab) were obtained from  
123 MyBioSource (clone number B215M, batches 2F17811 & 2F15911, USA). Bovine serum  
124 albumin (BSA, fraction V, 96–100% protein, batch SLB38588V), Horseradish peroxidase  
125 (HRP, EC 1.11.1.7, batch SLBF8268V, with a purity index of 1.9), Tween® 20 (impurities  
126  $\leq 3\%$  in water), o-phenylenediamine dihydrochloride (OPD-2HCl), hydrogen peroxide ( $\text{H}_2\text{O}_2$ ,  
127 30% (v/v) solution equivalent to a titer of 120V of oxygen (10.73 M) upon opening (Coussot *et*  
128 *al.*, 2018c)), Dulbecco's Phosphate Buffered Saline (DPBS, 10X solution, pH 7.4, used in a  
129 final concentration of 1X in water solvent), sulfuric acid ( $\text{H}_2\text{SO}_4$ ,  $\geq 97,5\%$ ), citric acid ( $\geq$   
130 99,5%), sodium hydroxide solution (10M solution for molecular biology), sodium phosphate  
131 dibasic dodecahydrate ( $\text{Na}_2\text{HPO}_4 \cdot 12\text{H}_2\text{O}$ ,  $\geq 99,0\%$ ), sodium bicarbonate ( $\text{NaHCO}_3$ ,  $\geq 99,5\%$ ),  
132 sodium carbonate ( $\text{Na}_2\text{CO}_3$ ,  $\geq 99,5\%$ ), D(+)-saccharose (sucrose,  $\geq 99,0\%$ ), L-Histidine (His,  
133  $\geq 99,0\%$ ), D-Arginine (Arg,  $\geq 99,0\%$ ), ethanol (EtOH,  $\geq 99,5\%$ ), hydrochloric acid (HCl, 37%),  
134 were purchased from Sigma Aldrich (Saint-Quentin Fallavier, France). Corning DNA Bind™  
135 8-well strip plate with N-hydroxysuccinimide modified surface (NHS-wells) were provided by  
136 Sigma Aldrich (Saint-Quentin Fallavier, France). NHS-wells were manufactured by Air  
137 Liquide (Sassenage, France) to fit perfectly with the shape and size of EXPOSE-R2 closed cells  
138 provided by the French Space Agency (CNES, Toulouse) (Vigier *et al.*, 2013), called simply  
139 “cells” in the following. These home-designed NHS-wells had a diameter of 8.4 mm with a 7.1  
140 mm height. Teflon cap were specially manufactured by Air Liquide to close these custom  
141 designed NHS-wells (Coussot *et al.*, 2018d). The ultra-pure water was obtained from a  
142 Millipore Purification system. Other chemicals are analytical grade and used as received.  
143 During the assays, the relative humidity and air temperature were controlled using a

144 thermohygrometer Testo 605-H1 (Type 05600610, identification number 39227197/205),  
145 equipment whose calibration is traceable to national standards (certificate number 1306125).  
146 During all assays, room temperature was  $23.2\pm 1.3^{\circ}\text{C}$ , and recorded relative humidity (RH) was  
147  $25.7\pm 0.9\%$ .

148

## 149 *II.2 Sample preparation*

150 Long-time exposure to real space conditions during the EXPOSE-R2 mission were evaluated  
151 on freeze-dried Ab in both covalently immobilized format (labelled “G” *for grafted*) and in-  
152 solution Ab format (free anti-HRP Ab labelled “F” *for free*). The immobilization strategy, the  
153 freeze-drying optimized procedure, the A2HRP validated protocol were detailed elsewhere  
154 (Coussot *et al.*, 2017, Coussot *et al.*, 2018a, Coussot *et al.*, 2018b, Coussot *et al.*, 2018c). The  
155 freeze-drying stock solution was freshly prepared and was composed of 1.05 g of citric acid  
156 (0.1M), 38.75 mg of His (5 mM), 52.5 mg of Arg (5 mM) in a final volume of 50 mL of water  
157 and adjusted to pH 6.5 with NaOH (10M) before adding 10  $\mu\text{L}$  of Tween®20.

158

### 159 *II.2a Preparation of anti-HRP Ab in free format*

160 The home-designed NHS-wells were filled up with 250  $\mu\text{L}$  of BSA (3% (w/v) in DPBS (1X)).  
161 After overnight reaction time at room temperature (RT) in the dark, the wells were emptied and  
162 rinsed three times with DPBST solution (DPBS (1X) with 0.05% (v/v) Tween®20) and three  
163 times with DPBS. An anti-HRP Ab solution was directly prepared at 200  $\mu\text{g}\cdot\text{mL}^{-1}$  in the above  
164 freeze-drying solution immediately before deposit into the BSA-saturated home-designed  
165 NHS-wells (noted also as inactivated BSA wells). In each inactivated BSA well, a volume of  
166 100  $\mu\text{L}$  of the anti-HRP Ab in the freeze-drying solution was mixed with 20  $\mu\text{L}$  of a freshly  
167 prepared sucrose solution (5g.L<sup>-1</sup> in water). The wells were placed within the homemade pre-



168 frozen aluminium block designed by our group, and kept frozen by adding liquid nitrogen to  
169 follow the optimized freeze-drying procedure (Coussot *et al.*, 2018c) as described in the section  
170 **II.3.**

171

### 172 *II.2b Preparation of anti-HRP Ab in covalently immobilized format*

173 The home-designed NHS-wells were filled up with a 200  $\mu\text{g.mL}^{-1}$  of anti-HRP Ab solution in  
174 DPBS (1X). After a minimum of 4h under gentle agitation at RT, a saturation step with 250  $\mu\text{L}$   
175 of BSA solution (3% w/v in DPBS) per well was carried out to prevent non-specific bindings  
176 (Baqué *et al.* 2011), followed by 3 washings with DPBST solution, and 3 washings with PBS.  
177 In each covalently immobilized and saturated Ab wells were added 100  $\mu\text{L}$  of the freeze-drying  
178 solution and 20  $\mu\text{L}$  of a freshly prepared sucrose solution (5g.L<sup>-1</sup> in water). Samples were then  
179 freeze-dried using the homemade aluminium holder as described in the section **II.3.**

180

### 181 *II.3 Freeze-drying procedure*

182 The aluminium holder had the advantage of running multiple samples at the same time avoiding  
183 freeze-drying batch effects. As described elsewhere, this device was pre-frozen and transferred  
184 into the central part of a freeze-dryer (Christ Alpha 2–4 from Martin Christ GmbH, Germany)  
185 (Coussot *et al.*, 2018c). Freeze-drying was performed overnight (condenser temperature  $-85^{\circ}\text{C}$ ,  
186 vacuum 0.05 mbar). When the freeze-drying process was achieved, the chamber of the freeze-  
187 dryer was filled with nitrogen gas before closing the sample-containing aluminium holder,  
188 which kept the samples hermetically sealed and sheltered them from the moisture and light until  
189 its opening. The opening of the aluminium holder was done in a glove box under a controlled  
190 atmosphere of helium (10% He) in argon (Ar) provided by Air Liquide (Sassenage, France) to  
191 maintain a RH level of 10% to 15%. During our experiments in the glove box, the RH and air

192 temperature were controlled using a thermohygrometer Testo 605-H1 (Testo, France). RH was  
193  $12\pm 3\%$  and air temperature was  $22.8\pm 2.3^\circ\text{C}$ . After opening the aluminium holder, freeze-dried  
194 samples were capped and directly transferred into the CNES closed cells using a tool vacuum  
195 suction pen (FFQ939 from Mayf's Online Shop, China). Into each cell, two  
196 ThermoLuminescent Dosimeters (TLDs) were placed at the bottom of the cell, below the  
197 samples. These passive dosimeters were analyzed at the end of the mission. The absorbed dose  
198 measured into the cells was 220 mGy that corresponds to the dose that can be expected during  
199 a mission to Mars including 8 months travel and 18 months at Mars surface. (Hassler *et al.*,  
200 2014; Coussot *et al.*, 2018d). The cells were then screwed with a final tightening of 0.7 Nm  
201 using a torque screwdriver TorqueVario®-S (Wiha, Germany) (Vigier *et al.*, 2013; Coussot *et*  
202 *al.*, 2018d).

203

#### 204 *II.4 Experiment outside the International Space Station (ISS)*

205 To study the impact of all constraints encountered by a biochip during an entire space mission  
206 (long duration storage, transportation, take-off/landing shocks, thermal constraints, and  
207 cumulative effects of cosmic rays particles), 41 anti-HRP Ab samples (21 anti-HRP Ab in the  
208 free format “F” and 20 in the covalently immobilized format “G”) took part of the “Biochip in  
209 PSS experiment” (Vigier *et al.*, 2013; Cottin *et al.*, 2015) during the EXPOSE-R2 mission. An  
210 overall view of EXPOSE-R2 mission is illustrated in **Figure 1**. All samples (14 exposed on ISS  
211 and 27 kept on Earth) were simultaneously prepared, within the same freeze-drying batch, as  
212 described in the experimental section *II.3*. The 14 exposed cells were spread on the 2 exposure  
213 levels of the Tray 3 of the EXPOSE carrier dedicated to the PSS experiment (4F and 3G anti-  
214 HRP Ab in each level). Disposition of the exposed cells on the sample carrier was the same for  
215 the upper and the lower level of the tray 3 (denoted as upper tray and lower tray, respectively).

216 Launch to ISS (July 23<sup>th</sup>, 2014) and storage inside ISS was at ambient temperature (22-25°C  
217 on average) (Rabbow *et al.*, 2017). Then, the EXPOSE-R2 platform was placed outside the ISS  
218 on the Universal platform D on August 18<sup>th</sup> with opening of the valves for venting the inner  
219 part of EXPOSE-R2 on August 20<sup>th</sup>, and removal of the UV shield in October 22<sup>nd</sup>, 2014. On  
220 February 3<sup>rd</sup>, 2016 trays were covered and brought back inside the ISS. Thus, the exposed  
221 samples spent 566 days outside the ISS over the 588 days of the mission (1 year, 8 months).

222 During their extravehicular exposition, the samples on Tray 3 were submitted to radiations and  
223 temperatures varying between -20.9 °C and 57.98 °C (Rabbow *et al.*, 2017). On March 2<sup>nd</sup> 2016,  
224 EXPOSE-R2 Tray 3 landed on Earth. During transit from the Baikonur cosmodrome to  
225 Moscow, and from Moscow to the German Aerospace Center (DLR, Germany) a recording of  
226 temperatures was done, the temperatures oscillated between 20°C and 24°C, then from DLR to  
227 LISA (Laboratoire Interuniversitaire des Systèmes Atmosphériques, Créteil, France) (Rabbow  
228 *et al.*, 2017), and from Créteil to Montpellier a controlled chamber at 4°C was used during  
229 transportation in the summer period. De-integration of the exposed cells from the sample  
230 carriers was done according to MUSC/DLR/ESA/CNES internal procedures (Rabbow *et al.*,  
231 2017). On June 24<sup>th</sup> 2016, the soldered joint of all the cells (including ground references) was  
232 removed, using a mechanical lathe and a manufactured CNES tool, in the mechanics department  
233 of the Montpellier University (Coussot *et al.*, 2018d). Samples were immediately sealed in a  
234 FoodSaver™ bag (Fischer Scientific, France) and stored in the dark at 4°C until analysis with  
235 the A2HRP method (section **II.7**)

236

## 237 ***II.5 EXPOSE-R2 mission ground references***

238 During the same period, experiments were performed on ground to control the long-term  
239 behaviour of anti-HRP Ab upon storage but not exposed to space conditions. A total of twenty-  
240 seven mission ground controls were studied. Six ground cells (3F and 3G anti-HRP Ab) were  
241 stored at the French Space Agency (CNES, Toulouse) by maintaining an accurate temperature  
242 control at  $3.9^{\circ}\pm 0.8^{\circ}\text{C}$  over that period. Twenty-one ground cells were kept in DLR (Cologne,  
243 Germany): six ground cells (3F and 3G anti-HRP Ab) were stored at  $5^{\circ}\text{C}$  and eight ground cells  
244 (4F and 4G anti-HRP Ab) underwent the same thermal history as ISS samples (DLR  $\Delta\text{T}$ ), and  
245 seven ground samples (4F and 3G anti-HRP Ab) were stored in conditions combining long time  
246 storage, varying thermal environment as ISS ones, and UV radiations (DLR  $\Delta\text{T}+\text{UV}$ ) (Rabbow  
247 *et al.*, 2017). All of these 27 ground cells were brought back to Montpellier to be analyzed  
248 simultaneously with the 14 exposed cells during all the desoldering process and  $4^{\circ}\text{C}$  storage  
249 before rehydration. For the free format, rehydration was done with  $100\ \mu\text{L}$  of water and  $20\ \mu\text{L}$   
250 of carbonate-bicarbonate buffer ( $0.1\text{M}$ , pH 9.2) per well in order to fix the pH of the sucrose-  
251 containing freeze drying Ab solution to 7.4 to preserve Ab functionality. Free Ab were then  
252 covalently coupled to NHS-wells following the procedure described in section **II.2b**. For the  
253 grafted format, rehydration was carried out with  $120\ \mu\text{L}$  of DPBS. The rate of functional Ab in  
254 both formats was determined with the A2HRP method (section **II.7**, **Figure 1C**).

### 255 ***II.6 Additional ground thermal cycling experiments***

256 The anti-HRP Ab were freeze-dried in both formats as described in section **II.3**. Thermal  
257 cycling experiments were carried out on freeze-dried samples in their sealed bags in a  
258 temperature test chamber (Vötsch VT 4004). Two independent thermal variation experiments  
259 were done: one with a sharp rise in temperature ( $5^{\circ}\text{C}/\text{min}$ ) reaching a one-hour plateau at  $80^{\circ}\text{C}$   
260 (referred as “ $80^{\circ}\text{C}$  peak” in the text), and a long cycling period (178.8 hours or 7.45 days)  
261 mimicking thermal variations of exposed cells (see Coussot *et al.*, 2018d) with an amplitude of

262 about 70°C (referred as “long cycle” in the text). Samples were rehydrated as described above  
263 and analyzed with the A2HRP method.

264

### 265 ***II.7 Validated A2HRP method and data interpretation***

266 For all ground-based experiments and that of the overall ISS mission, the A2HRP method  
267 **(Figure 1C)** was used to evaluate the functionality of anti-HRP Ab towards its antigen HRP.  
268 Briefly, the principles are as following: once the anti-HRP Ab were immobilized onto the NHS-  
269 wells to reach a density of  $3.9 \times 10^{11}$  antibody per  $\text{mm}^2$  (section **II.2b**)(Moreau *et al.*, 2011), a  
270 HRP stock solution ( $1 \text{ g.L}^{-1}$ ) was prepared by dissolving the enzyme in a stabilizing solution  
271 composed of 0.1 M  $\text{Na}_2\text{HPO}_4$  and 0.05M citric acid, pH 5.2. A HRP working solution at 200  
272  $\mu\text{g.mL}^{-1}$  was prepared immediately before use from the HRP stock solution by dilution in  
273 DPBS. A volume of 110  $\mu\text{L}$  of the HRP working solution was pipetted into wells containing  
274 the previously grafted anti-HRP antibody to saturate all of its binding sites (Moreau *et al.*,  
275 2011). At least 2 hours at RT or overnight incubations were considered for maximal binding of  
276 HRP to anti-HRP Ab surfaces. Unbound HRP was removed by rinsing 3 times with DPBST  
277 and 3 more times with DPBS. The wells were then incubated with a freshly prepared *o*-  
278 phenylenediamine dihydrochloride/hydrogen peroxide (OPD/ $\text{H}_2\text{O}_2$ ) solution. The OPD/ $\text{H}_2\text{O}_2$   
279 reaction solution was composed of 1 mL OPD stock solution at  $5 \text{ g.L}^{-1}$  in deionized water, 8.6  
280 mL of stabilizing solution described above, and 400  $\mu\text{L}$  of 30%  $\text{H}_2\text{O}_2$ . 50  $\mu\text{L}$  of this OPD/ $\text{H}_2\text{O}_2$   
281 reaction solution and 50  $\mu\text{L}$  of stabilizing solution were mixed into each well. The  
282 HRP/OPD/ $\text{H}_2\text{O}_2$  reaction that converts OPD to 2,3-diaminophenazine (DAP) was then stopped  
283 after 4 min by adding 30  $\mu\text{L}$  of STOP solution ( $\text{H}_2\text{SO}_4$ , 4N,  $\text{pH}<1$ ). The HRP-catalyzed OPD  
284 oxidation into DAP was recorded at 490 nm with an Infinite 200<sup>TM</sup> absorbance microplate  
285 reader from Tecan (Lyon, France). The activity of the Ab surfaces is expressed as a percentage

286 of the sample/reference ratio of its net absorbance values. The net absorbance values correspond  
287 to the measured assay values minus the mean absorbance of the blank obtained with inactivated  
288 BSA-wells (section *II.2a*).

289 All data were reported as the mean  $\pm$  the standard deviation (SD) from at least three replicate  
290 experiments. Statistical significance of the assays was determined using Student's *t* test  
291 ( $p=0.05$ ).

292

### 293        **III.    Results**

294    Stress affects Ab performances in different ways depending on the type and duration of the  
295    event (Coussot *et al.*, 2018b; Coussot *et al.*, 2018c). Irradiation effects on anti-HRP Ab was  
296    assessed here by evaluating the functionality of the anti-HRP Ab before and after the stress  
297    event or by comparing the activity of exposed Ab samples to that of non-exposed ones (named  
298    ground references (GR) or controls, see above). Analyses were done according to the validated  
299    A2HRP method (**Figure 1C**). The A2HRP method was demonstrated to have the potential for  
300    analyzing the binding ability of the anti-HRP Ab in both formats even if deleterious events  
301    occurred on the anti-HRP Ab before its coupling to the surface (Coussot *et al.*, 2018c). This  
302    direct assay permits a precise and reliable quantitation of HRP bound on the immobilized Ab  
303    surface, and consequently to evaluate the anti-HRP Ab binding capacities. It has also  
304    demonstrated its suitability to evaluate discrepancies in Ab bindings after their exposure to  
305    short-term irradiation events or forced degradation studies (Baqué *et al.* 2017, Coussot *et al.*,  
306    2017; Coussot *et al.*, 2018a; Coussot *et al.*, 2018b; Coussot *et al.*, 2018c). In the present paper,  
307    we evaluate the Ab resistance after their exposure to real space conditions, and thus for the first  
308    time the effect of cumulative and long-term stress events on the performance of a grafted Ab.  
309    In order to broadly represent any future Ab-based biochip instruments, we evaluated in a second  
310    part, free Ab format since both free and grafted Ab are considered for future applications in  
311    planetary exploration.

312

#### 313        ***III.1. Resistance of anti-HRP Ab in its grafted format after exposure outside the ISS***

314    Since radiation gradients were observed on the EXPOSE platform in previous ISS missions  
315    (Berger *et al.*, 2012), the 14 exposed Ab “Flight samples” were spread on the 2 exposure levels  
316    of the Tray 3 of the EXPOSE carrier dedicated to the PSS experiment, but with the same

317 disposition on the upper and the lower level of the carrier. All the experiments performed on  
318 grafted Ab are reported in **Figure 2**. To only take into account the effects encountered during  
319 the ISS mission (flights, extravehicular exposure, and all transportations during the mission),  
320 the percentage of functional Ab is calculated using the freeze-dried ground samples stored at  
321 5°C in DLR facility ( $n=2$  replicates) during all the duration of the mission. At first view, the  
322 results reveal a possible degradation of several samples including flight samples. Higher  
323 variability in the estimated recognition capabilities of our Ab has been observed when using  
324 custom designed NHS-wells with a within-assay precision equals of 10.3% for that custom  
325 designed wells batch, in comparison with conventional ones (within-assay precision is less than  
326 7.1%; Coussot *et al.*, 2018b). The effects of transportation are evaluated by confronting activity  
327 of ground controls stored in DLR with that of CNES ground samples. Remaining activity of  
328 both CNES and DLR grounds controls, are not statistically different (Student's *t*-test). No  
329 significant effect is also observed with the ground sample named DLR  $\Delta T+UV$ , which  
330 combines long time storage, varying thermal environment mimicking ISS ones, and UV  
331 radiations. To complement these data, we run here additional ground thermal cycling  
332 experiments to evaluate whether an effect due to a long-term exposure to temperature variations  
333 during the mission can be invoked. Ground thermal cycling experiments were carried out on  
334 the anti-HRP Ab over a 80°C short peak of temperature, a long cycle mimicking thermal  
335 variations of flight samples (see **section II.6** of the experimental part), and compared with an  
336 identical storage time at 4°C. All assays were performed with eight replicates. Ab activities are  
337 presented in **Figure 3**. A degradation of 1/3 of initially active grafted Ab (corresponding to  
338 66% of surface active Ab) is shown during the freeze-drying process by comparing data  
339 obtained with fresh G Ab that did not undergo freeze-drying with that of rehydrated sample  
340 upon opening of the aluminium holder (**Figure 3**, first two shaded bars with grey lines). In  
341 addition, comparing results from the overall process, cumulating the freeze-drying step and



342 storage, shaded grey bars indicate a slight but significant difference in activity between the three  
343 stored freeze-dried samples (55.1±4.1 for the 4°C storage; 48.5±3.2 for the 80°C peak; 46.7±4.1  
344 during the long cycle) and the freeze-dried sample analysed with no storage (66.8±6.7) whereas  
345 the percent Ab activity values after the sole freeze-drying process are 83.1±14.5, 69.8±13.1,  
346 and 72.5±12.1 for the freeze dried 4°C storage, the 80°C peak, and long cycle, respectively,  
347 indicating that there were not significant differences ( $p>0.05$ ) between the reference sample  
348 with no storage and the 3 stored ones (**Figure 3**, filled grey bars).

349

### 350 *III.2. Resistance of anti-HRP Ab in free format after exposure outside the ISS*

351 Since a 30% functional activity difference in freeze-dried Ab, between the free format and the  
352 covalently immobilized one, has been reported in literature depending on the freeze-drying  
353 formulation components (Coussot *et al.*, 2018c), and that only free Ab format has been studied  
354 in previous experiments on the BIOPAN-6 low Earth orbit platform (Derveni *et al.*, 2012;  
355 Derveni *et al.*, 2013), the resistance of free anti-HRP Ab after exposure to real space conditions  
356 is detailed hereafter.

357 Previous data using the same freeze-drying solution adjusted to pH 7.4 for Ab immobilization  
358 to the NHS-wells showed that free Ab activity losses under 25±2% could not be quantified with  
359 the A2HRP method due to sample preparation, multi-step procedure, and handlings (Coussot  
360 *et al.*, 2018c). However, the A2HRP method has the advantage of providing reliable and precise  
361 data for stability studies of the free anti-HRP Ab, by comparing with conventional competitive  
362 inhibition assays. Indeed, changes in Ab properties upon degrading conditions were proved to  
363 dramatically affect the data in conventional immunoassays with high variability of the results.  
364 It is also restricted to competitive mechanism of inhibition; if other mechanisms occurred at the  
365 same time in the sample it would generate uninterpretable data. All the results from the

366 EXPOSE-R2 mission samples illustrated in **Figure 4**, were obtained with the A2HRP method.  
367 No significant alteration of the free anti-HRP Ab is observed after both 80°C peak and long  
368 cycle exposures (data from ground experiments not shown). As shown by Coussot *et al.* 2018c,  
369 a possible additional air moisture degrading effect might have occurred during the storage of  
370 the freeze-dried F anti-HRP Ab at 4°C (sealed bag not perfectly hermetic). Owing to the  
371 inherent conditions of the rehydration step, this result is not surprising and correlates well with  
372 the above observations on the freeze-dried G Ab, and that of free GR stored in DLR  
373 ( $73.7\pm 10.3\%$ ). Consequently, considering all the results presented in **Figure 4**, no significant  
374 differences ( $p>0.05$ ) are observed in the binding activity of the anti-HRP Ab, under its free  
375 format, with the same order of activity for the flight samples as for the ground ones. As before,  
376 a 37% drop in remaining free Ab activity is necessary to detect alterations in Ab binding  
377 efficiency from cosmic radiations during flight samples exposure outside the ISS.

378

#### 379 **IV. Discussion**

380 In this study, we evaluated the effect due to a long-term exposure to temperature variations on  
381 the activity of anti-HRP Ab in its grafted format but independently from flight samples (**Figure**  
382 **3**). Indeed, the effect of short exposure of covalently grafted Ab at elevated temperatures was  
383 previously published (Coussot *et al.*, 2018c). It revealed that about 60% of the initial activity  
384 of covalently immobilized Ab was preserved during short temperature stress. We reported also  
385 that freeze-dried samples suffered less from stress due to temperature exposure than from the  
386 rehydration step, probably due to changes in composition of the solid form upon contact with  
387 air moisture, which was supposed to lead to only a partial refolding of the freeze-dried Ab.  
388 Thus, after exposure of grafted Ab to thermal variations, activity changes, if they occurred,  
389 might not be due to an effect of temperature but rather from storage time. Indeed, the results of

390 remaining Ab activity after the freeze-drying process show no discrepancy ( $p>0.05$ ) between  
391 the reference sample with no storage and the 3 stored ones (**Figure 3**, filled grey bars). This  
392 means that an alteration of Ab bindings other than those occurring during the freeze-drying  
393 process/rehydration or thermal variations might be evoked only if there is more than 40% drop  
394 in remaining Ab activity (from freeze-dried control) after a long-duration experiment. This is  
395 consistent with tests done on GR samples illustrated in **Figure 2**.

396 Measurements performed with passive dosimeters during the EXPOSE-R2 mission revealed, a  
397 posteriori, that the absorbed dose difference between cells at upper and lower levels was low  
398 (about 3 mGy for the whole mission corresponding to 1.4% of the total). We explained this  
399 difference due to an estimated shielding of TLDs of 0,82 g/cm<sup>2</sup> on the upper level (Cousot *et*  
400 *al.*, 2018d) so the absorbed dose remains quasi uniform between the two levels. This can explain  
401 why the results we obtained for the “upper tray” and the “lower tray” samples have no statistical  
402 differences. Indeed, we obtained a remaining activity of 50.6±9.0% for the flight “upper tray”  
403 samples, and 62.9±11.0% for the flight “lower tray” for grafted Ab (**Figure 2**). For free format,  
404 our results showed that a 37% drop in remaining free Ab activity is necessary to detect  
405 alterations in Ab binding efficiency. In other words, this shows that much more than 63% of  
406 the free anti-HRP Ab are still functional after their long-duration exposure outside the ISS  
407 (**Figure 4**). Consequently, based on all the above considerations, our results show that grafted  
408 and free Ab partially keep their recognition capabilities during the overall flight mission, and  
409 that the degradations from cosmic radiations, if any, are too small to be detected by our analysis  
410 protocols.

411 Nevertheless, due to the high number of potentially hazardous factors encountered during a  
412 space mission (McKenna-Lawlor *et al.*, 2012), our experiment demonstrates with confidence,

413 for the first time, that much more than 40% of Ab (whatever the format) survived to the long-  
414 duration exposure outside the ISS and remained functional.

415

416 Antibody-based biochips have not been used yet for planetary exploration missions although  
417 their high potential for searching tracers of extinct or extant life (Parro *et al.* 2011c). One major  
418 concern for an instrument based on this technology is radiation effect issues on the antibodies.  
419 Many laboratory experiments have been performed so far at different energies with different  
420 particles and high fluences (much more important than suspected for a mission to Mars for  
421 instance) to test the ability of antibodies to recognize their target after radiation exposure (Le  
422 Postollec *et al.*, 2009a; Le Postollec *et al.*, 2009b; Baqué *et al.*, 2011; de Diego *et al.*, 2011;  
423 Baqué *et al.*, 2017; Coussot *et al.*, 2017). A 12 days mission on the BIOPAN-6 low-earth orbit  
424 platform has been performed to study the effects of cumulative irradiations on two antibodies'  
425 ability to bind to their respective antigens (Derveni *et al.*, 2012; Derveni *et al.*, 2013). In the  
426 present paper, we improved previous studies to better test the effects of real-space constraints  
427 on antibodies during an EXPOSE-R2 mission outside the International Space Station. In terms  
428 of radiation, the total accumulated radiation dose recorded by the dosimeters during the  
429 EXPOSE-R2 is 220 mGy, which is much higher than those measured during the BIOPAN-6  
430 low Earth orbit experiment (2.4 mGy) (Derveni *et al.*, 2012), and is in agreement with the  
431 absorbed dose expected during a mission to Mars (Hassler *et al.* 2014, Le Postollec *et al.*  
432 2009a). All these studies show two major results: (1) the preparation procedure and analytical  
433 steps have to be controlled and validated with care to obtain reliable results. (2) no clear  
434 deleterious effect have been reported so far on the antibody and antigen recognition step, in the  
435 limit of detection of the analysis protocols.

436 As a consequence, to our opinion, radiation effects on the antibodies should not be considered  
437 anymore as an issue for antibody-based instruments dedicated to a planetary mission (in  
438 particular for the exploration of Mars).

439

#### 440 **IV. Conclusions**

441 The aim of our study was to test whether space flight conditions might have influences on the  
442 performances of Ab-based biochips. A direct, precise and reliable assay was used to evaluate  
443 the remaining activity of ground controls and flight samples that underwent long-term storage,  
444 temperature variations, and shocks all along the EXPOSE-R2 mission. The results presented in  
445 this paper show that cosmic radiation has no significant effect on the antibody recognition  
446 ability, independent of the exposed format, *free* or *immobilized onto a solid surface*. These  
447 results are in agreement with all the previous ground-based experiments performed on  
448 irradiation facilities with different particles at various energies.

449 In that experiment, since we precisely managed all the steps of the analytical protocol and of  
450 the sample conditioning under controlled atmosphere, and with all the necessary steps to  
451 consider during the overall mission (**Figure 1**), we clearly demonstrated the relevance and  
452 adequacy of antibody based instruments to be used for future planetary exploration  
453 experiments.

454

455

456 **Acknowledgments**

457 The authors would like to thank the French national space agency (CNES) for financial support  
458 (05/2182/00-DCT094). The authors thank Jean-Louis Kergueme from the Mechanics  
459 Department of the Montpellier University for his assistance during the desoldering of the cells,  
460 and Drs. Sonia Khier & Yann Ladner for their assistance that has led to good progress during  
461 the analysis of samples.

462

463 **References**

464 Baqué, M., Le Postollec, A., Coussot, G., Moreau, T., Desvignes, I., Incerti, S., Moretto, P.,  
465 Dobrijevic, M., Vandenabeele-Trambouze, O. (2011a) Biochip for astrobiological  
466 applications: Investigation of low energy protons effects on antibody performances. *Planetary*  
467 *and Space Science* 59(13):1490 – 1497.

468  
469 Baqué, M., Dobrijevic, M., Le Postollec, A., Moreau, T., Faye, C., Vigier, F., Incerti, S.,  
470 Coussot, G., Caron, J., Vandenabeele-Trambouze, O. (2017) Irradiation effects on antibody  
471 performance in the frame of biochip-based instruments development for space exploration.  
472 *International Journal of Astrobiology* 16(1): 82-90.

473  
474 Berger, T., Hajek, M., Bilski, P., Koerner, C., Vanhavere, F., Reitz, G. (2012). Cosmic  
475 radiation exposure of biological test systems during the EXPOSE-E mission. *Astrobiology*  
476 12(5): 387–392.

477  
478 Cottin, H., Saiagh, K., Nguyen, D., Grand, N., Benilan, Y., Cloix, M., Coll, P., Gazeau, M-C.,  
479 Fray, N., Khalaf, D., Raulin, F., Stalport, F., Carrasco, N., Szopa, C., Chaput, D., Bertrand,  
480 M., Westall, F., Mattioda, A., Quinn, R., Ricco, A., Santos, O., Baratta, G., Strazzulla, G.,  
481 Palumbo, M.E., Le Postollec, A., Dobrijevic, M., Coussot, G., Vigier, F., Vandenabeele-  
482 Trambouze, O., Incerti, S., Berger, T. (2015) Photochemical studies in low Earth orbit for  
483 organic compounds related to small bodies, Titan and Mars. *Current and future facilities*,  
484 *Bulletin de la Société Royale des Sciences de Liège* 84 : 60-73.

485  
486 Coussot, G., Moreau, T., Faye, C., Vigier, F., Baqué, M., Le Postollec, A., Incerti, S.,  
487 Dobrijevic, M., Vandenabeele-Trambouze, O. (2017) Biochip-based instruments development  
488 for space exploration: influence of the antibody immobilization process on the biochip  
489 resistance to freeze-drying, temperature shifts and cosmic radiations. *International Journal of*  
490 *Astrobiology* 16(2):190-199.

491  
492 Coussot, G., Faye, C., Le Postollec, A., Dobrijevic, M. (2018a) One-step direct immunoassay  
493 with horseradish peroxidase as antigen for studying the functionality of antibody surfaces.  
494 *Talanta*, 178:922-927.

495  
496 Coussot, G., Faye, C., Le Postollec, A., Dobrijevic, M. (2018b) A gold standard method for  
497 the evaluation of antibody-based materials functionality: Approach to forced degradation  
498 studies. *Journal of Pharmaceutical and Biomedical Analysis*, 152:17-24.

499  
500 Coussot, G., Faye, C., Le Postollec, A., Dobrijevic, M. (2018c) A methodological approach  
501 for the thermal stability and stress exposure studies of a model antibody. *Analytical*  
502 *Biochemistry*, 548: 23-31.

503

504 Coussot, G., Le Postollec, A., Incerti, S., Baqué, M., Faye, C., Vandenabeele-Trambouze, O.,  
505 Cottin, H., Ravelet, C., Peyrin, E., Fiore, E., Vigier, F., Caron, J., Chaput, D., Przybyla, B.  
506 Berger, T., Dobrijevic, M. (2018d) Photochemistry on the Space Station - Aptamer resistance  
507 to space constraints: particles exposure from irradiation facilities and real exposure outside the  
508 International Space Station. *Astrobiology*, submitted in April 2018.  
509

510 de Diego-Castilla, G., Cruz-Gil, P., Mateo-Martí, E., Fernández-Calvo, P., Rivas, L.A., Parro,  
511 V. (2011) Assessing antibody microarrays for space missions: effect of long-term storage,  
512 gamma radiation, and temperature shifts on printed and fluorescently labeled antibodies.  
513 *Astrobiology* 11(8):759–773.  
514

515 Derveni, M., Allen, M., Sawakuchi, G.O., Yukihara, E.G., Richter, L., Sims, M.R., Cullen,  
516 D.C. (2013) Survivability of immunoassay reagents exposed to the space radiation  
517 environment on board the ESA BIOPAN-6 Platform as a prelude to performing  
518 immunoassays on Mars. *Astrobiology* 13(1):93-102.  
519

520 Derveni, M., Hands, A., Allen, M., Sims, M.R., & Cullen, D.C. (2012) Effects of simulated  
521 space radiation on immunoassay components for Life-detection experiments in planetary  
522 exploration missions. *Astrobiology* 12(8): 718–729.  
523

524 Hassler, D M., Zeitlin, C., Wimmer-Schweingruber, R F.; Ehresmann, B.; Rafkin, S.;  
525 Eigenbrode, J L.; Brinza, D E.; Weigle, G.; Böttcher, S.; Böhm, E.; and 438 coauthors (2014)  
526 Mars' Surface Radiation Environment Measured with the Mars Science Laboratory's Curiosity  
527 Rover. *Science* 343 (6169), id. 1244797.  
528

529 Le Postollec, A. , Dobrijevic, M., Incerti, S., Moretto, P., Sez nec, H., Desorgher, L., Santin,  
530 G., Nieminen, P., Dartnell, L., Vandenabeele-Trambouze, O., Coussot, G. (2007)  
531 Development of a Biochip dedicated to planetary exploration. First step: resistance studies to  
532 space conditions. Journées Semaine de l' Astrophysique Française 2007.  
533

534 Le Postollec, A., Incerti, S., Dobrijevic, M., Desorgher, L., Santin, G., Moretto, P.,  
535 Vandenabeele-Trambouze, O., Coussot, G., Dartnell, L., Nieminen, P. (2009a) Monte Carlo  
536 simulation of the radiation environment encountered by a biochip during a space mission to  
537 Mars. *Astrobiology* 9(3): 311–323.  
538

539 Le Postollec, A., Coussot, G., Baqué, M., Incerti, S., Desvignes, I., Moretto, P., Dobrijevic,  
540 M., Vandenabeele-Trambouze, O. (2009b) Investigation of Neutron Radiation Effects on  
541 Polyclonal Antibodies (IgG) and Fluorescein Dye for Astrobiological Applications.  
542 *Astrobiology* 9(7): 637–645.  
543

544 Moreau, T., Faye, C., Baqué, M., Desvignes, I., Coussot, G., Pascal, R., Vandenabeele-  
545 Trambouze, O. (2011) Antibody-based surfaces: rapid characterization using two  
546 complementary colorimetric assays. *Analytica Chimica Acta* 706: 354-360.



547 Martins, Z. (2011) In situ biomarkers and the Life Marker Chip. *Astronomy & Geophysics*  
548 52(1):1.34 - 1.35.

549

550 McKay, C.P., Stoker, C.R., Glass, B.J., Davé, A., Davila, A.F., Heldmann, J.L., Marinova,  
551 M.M., Fairen, A.G., Quinn, R.C., Zacny, K.A., Paulsen, G., Smith, P.H., Parro, V., Andersen,  
552 D.T., Hecht, M.H., Lacelle, D., Pollard, W.H. (2013) The Icebreaker Life Mission to Mars: A  
553 Search for Biomolecular Evidence for Life. *Astrobiology* 13(4): 334–353.

554

555 McKenna-Lawlor, S., Gonçalves, P., Keating, A., Reitz, G., Matthiä, D. (2012) Overview of  
556 energetic particle hazards during prospective manned missions to Mars. *Planetary and Space*  
557 *Science* 63–64(0): 123–132.

558

559 Parro, V., Rodríguez-Manfredi, J.A., Briones, C., Compostizo, C., Herrero, P.L., Vezb, E.,  
560 Sebastián, E., Moreno-Paz, M., García-Villadangos, M., Fernández-Calvo, P., González-  
561 Toril, E., Pérez-Mercader, J., Fernández-Remolar, D., Gómez-Elvira, J. (2005) Instrument  
562 development to search for biomarkers on Mars: Terrestrial acidophile, iron-powered  
563 chemolithoautotrophic communities as model systems. *Planetary and Space Science*  
564 53(7):729-737.

565

566 Parro, V., Fernández-Remolar, D., Rodríguez-Manfredi, J.A., Cruz-Gil, P., Gómez-Elvira, J.  
567 (2008) SOLID2: an antibody array-based Life-detector instrument in a Mars drilling  
568 simulation experiment (MARTE). *Astrobiology* 8(5): 987–999.

569

570 Parro, V., Fernández-Remolar, D., Rodríguez-Manfredi, J.A., Cruz-Gil, P., Rivas, L.A., Ruiz-  
571 Bermejo, M., Moreno-Paz, M., García-Villadangos, M., Gómez-Ortiz, D., Blanco-López, Y.,  
572 Menor-Salván, C., Prieto-Ballesteros, O., Gómez-Elvira, J. (2011a) Classification of modern  
573 and Old Rio Tinto sedimentary deposits through the biomolecular record using a Life Marker  
574 Biochip: Implications for detecting life on Mars. *Astrobiology* 11(1): 29–44.

575

576 Parro, V., de Diego-Castilla, G., Rodríguez-Manfredi, J.A., Rivas, L.A., Blanco-López, Y.,  
577 Sebastián, E., Romeral, J., Compostizo, C., Herrero, P.L., García-Marín, A., Moreno-Paz, M.,  
578 García-Villadangos, M., Cruz-Gil, P., Peinado, V., Martín-Soler, J., Pérez-Mercader, J.,  
579 Gómez-Elvira, J. (2011b) SOLID3: a multiplex antibody microarray-based optical sensor  
580 instrument for in situ Life detection in planetary exploration. *Astrobiology* 11(1): 15–28.

581

582 Parro, V., de Diego-Castilla, G., Moreno-Paz, M., Blanco, Y., Rodríguez-Manfredi, J.A.,  
583 Fernández-Remolar, D., Gómez, F., Gómez, M.J., Rivas, L.A., Demergasso, C., Echeverría,  
584 A., Urtuvia, V.N., Ruiz-Bermejo, M., García-Villadangos, M., Postigo, M., Sánchez-Román,  
585 M., Chong-Díaz, G., Gómez-Elvira, J. (2011c) A microbial oasis in the hypersaline Atacama  
586 subsurface discovered by a Life Detector Chip: Implications for the search for Life on Mars.  
587 *Astrobiology* 11(10): 969–996.

588

589 Rabbow, E., Rettberg, P., Parpart, A., Panitz, C., Schulte, W., Molter, F., Willnecker, R.  
590 (2017). EXPOSE-R2: The Astrobiological ESA Mission on Board of the International Space  
591 Station. *Frontiers in Microbiology*, 8, 1533. <http://doi.org/10.3389/fmicb.2017.01533>.  
592

593 Sims, M.R., Pullan, D., Holt, J., Blake, O., Sykes, J., Samara-Ratna, P., Canali, M., Cullen,  
594 D.C., Rix, C.S., Buckley, A., Derveni, M., Evans, D., Miguel García-Con, L., Rhodes, A.,  
595 Rato, C.C., Stefinovic, M., Sephton, M.A., Court, R.W., Bulloch, C., Kitchingman, I., Ali, Z.,  
596 Borst, G., Leeuwis, H., Prak, A., Norfini, A., Geraci, E., Tavanti, M., Brucato, J., Holm, N.  
597 (2012) Development status of the life marker chip instrument for ExoMars. *Planetary and  
598 Space Science* 72(1): 129–137.

599

600 Smith, H., Parro, V. (2014) Planetary Protection Plan for an Antibody based instrument  
601 proposed for Mars2020. in *40<sup>th</sup> COSPAR Scientific Assembly*. p. 3140.  
602

603 Vigier, F., Le Postollec, A., Coussot, G., Chaput, D., Cottin, H., Berger, T., Triqueneaux, S.,  
604 Dobrijevic, M., Vandenabeele-Trambouze, O. (2013) Preparation of the Biochip experiment  
605 on the EXPOSE-R2 mission outside the International Space Station. *Advances in Space  
606 Research* 52(12): 2168–2179.  
607  
608

609 **Figure captions**

610 **FIG.1.** An overall view of the EXPOSE-R2 mission with two formats of freeze-dried anti-HRP  
611 antibody (Ab): first is grafted format (G) with Ab covalently immobilized on the well-surface  
612 and second is free format (F) with Ab prepared *in-solution*.

613 **IA) Pre-flight samples preparation** with 1) Freeze-drying procedure, conditioning and screwing  
614 of the CNES cells under controlled atmosphere, in Montpellier; 2) Soldering of the CNES cells,  
615 integration of CNES cells into the trays, in Paris. Ground references (GR) were stored in CNES  
616 (Toulouse) and in DLR (Germany); 3) 56P launch from the cosmodrome in Baikonur,  
617 Kazakhstan.

618 **IB) EXPOSE-R2 flight** with 4) Integration of the trays into the EXPOSE-R monoblock, 26  
619 days stay inside ISS; 5) EVA-39, exposition outside the ISS; 6) EVA-40, removal of the sun  
620 shield; 7) EVA-42, end of exposure, return into the ISS and de-integration of the trays; 8) Return  
621 to ground, expedition 46 landing, 44S Soyuz capsule.

622 **IC) Post-flight experiments** with 9) Disassembly of the PSS carriers, and de-integration of the  
623 exposed cells. Ground references (21 GR in DLR and 6 GR in CNES that represent 14F + 13G)  
624 brought back to Montpellier; 10) Desoldering of the cells in Montpellier; 11) Analysis of freeze  
625 dried samples according to A2HRP method.

626 **ID) A2HRP method principle**. A decrease in the HRP-Ab binding events results in a decrease  
627 of the absorbance signal (*see* experimental part for details).


628 **FIG.2.** Binding activity of the grafted anti-HRP Ab obtained for ground controls (number of  
629 replicates: CNES  $n= 3$ ; DLR  $n= 2$ ; DLR  $\Delta T$   $n=4$ ; DLR  $\Delta T+UV$   $n=3$ ) and flight samples ( $n= 3$   
630 replicates for both lower and upper tray) by the A2HRP method. Each filled grey bar represents  
631 the mean and standard deviation (SD) of the Ab activity (normalized value in %, calculated  
632 against freeze-dried ground controls stored in DLR at 5°C ( $n=2$  replicates)).

633 **FIG.3.** Binding activity of the grafted anti-HRP Ab (G Ab) obtained without and after freeze-  
634 drying, without storage (instantaneous rehydration after freeze-drying), with storage at 4°C for  
635 freeze-dried control, with sharp rise in temperature (80°C peak), and a thermal cycling  
636 experiment mimicking thermal cells exposure outside the ISS (long cycle  $\Delta T$ ) but in accelerated  
637 time: one hour of EXPOSE-R2 mission was converted into one minute to carry out this  
638 experiment in the lab with similar temperature amplitude (for details see Coussot *et al.*, 2018d).  
639 Each bar represents the mean and standard deviation (SD) of the Ab activity ( $n= 8$  replicates,  
640 normalized value in %), calculated against freshly prepared Ab surface (shaded bars with grey  
641 lines) to evaluate cumulative effects or calculated against freeze-dried Ab without storage  
642 (filled grey bars) to evaluate the effects of storage and temperature.

643 **FIG.4.** Binding activity of the free anti-HRP Ab obtained for ground controls (number of  
644 replicates: CNES  $n= 3$ ; DLR  $n= 3$ ; DLR  $\Delta T$   $n=4$ ; DLR  $\Delta T+UV$   $n=4$ ) and flight samples ( $n= 3$   
645 replicates for both lower and upper tray) by the A2HRP method. Each dark bar represents the  
646 mean and standard deviation (SD) of the activity (normalized value in %, calculated against a  
647 freshly prepared freeze-dried ground reference).

648

FIG.1.




650

651

652

653


**FIG.2.**



654

655

**FIG.3.**



656


657

658

659

**FIG.4.**

660



661

662

663